IBEX BIOSCIENCES

Ibex Biosciences engages in a diverse approach to research and development. Ibex strives to discover, validate, and produce potential solutions to a multitude of serious challenges facing human and ecological health by investing in exploratory projects and processes that may not have been validated within the public research community. The company develops therapeutic antibodies, gene therapy, and stem cell programs intended to address unmet medical conditions plaguing humanity. Its robust port... folio focuses on three primary areas: (1) cancer and non-cancer therapeutic antibodies/intrabody: Ibex is producing and developing antibodies targeting multiple cancers including breast, prostate, glioblastoma, lung, and neuroblastoma; (2) Cancer Gene Therapy: Ibex is developing a gene therapy that targets multiple cancer cells in-vitro including glioblastoma, melanoma, and cervical; and (3) Diagnostic Antibodies: Ibex is developing a skin cancer initial diagnostic, a CIN (Cervical Intraepithelial Neoplasia) diagnostic, and an early-stage pancreatic cancer diagnostic. It was founded in 2015 and is headquartered in Cumberland, Maryland.

#People #Website #More